• Je něco špatně v tomto záznamu ?

Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells

H. Kostrhunova, BS. McGhie, L. Markova, O. Novakova, J. Kasparkova, JR. Aldrich-Wright, V. Brabec

. 2023 ; 66 (12) : 7894-7908. [pub] 20230607

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011011

The platinum(II) complex [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+ (PtII56MeSS, 1) exhibits high potency across numerous cancer cell lines acting by a multimodal mechanism. However, 1 also displays side toxicity and in vivo activity; all details of its mechanism of action are not entirely clear. Here, we describe the synthesis and biological properties of new platinum(IV) prodrugs that combine 1 with one or two axially coordinated molecules of diclofenac (DCF), a non-steroidal anti-inflammatory cancer-selective drug. The results suggest that these Pt(IV) complexes exhibit mechanisms of action typical for Pt(II) complex 1 and DCF, simultaneously. The presence of DCF ligand(s) in the Pt(IV) complexes promotes the antiproliferative activity and selectivity of 1 by inhibiting lactate transporters, resulting in blockage of the glycolytic process and impairment of mitochondrial potential. Additionally, the investigated Pt(IV) complexes selectively induce cell death in cancer cells, and the Pt(IV) complexes containing DCF ligands induce hallmarks of immunogenic cell death in cancer cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011011
003      
CZ-PrNML
005      
20230801132745.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.3c00269 $2 doi
035    __
$a (PubMed)37285472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kostrhunova, Hana $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, CZ-61200 Brno, Czech Republic
245    10
$a Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells / $c H. Kostrhunova, BS. McGhie, L. Markova, O. Novakova, J. Kasparkova, JR. Aldrich-Wright, V. Brabec
520    9_
$a The platinum(II) complex [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+ (PtII56MeSS, 1) exhibits high potency across numerous cancer cell lines acting by a multimodal mechanism. However, 1 also displays side toxicity and in vivo activity; all details of its mechanism of action are not entirely clear. Here, we describe the synthesis and biological properties of new platinum(IV) prodrugs that combine 1 with one or two axially coordinated molecules of diclofenac (DCF), a non-steroidal anti-inflammatory cancer-selective drug. The results suggest that these Pt(IV) complexes exhibit mechanisms of action typical for Pt(II) complex 1 and DCF, simultaneously. The presence of DCF ligand(s) in the Pt(IV) complexes promotes the antiproliferative activity and selectivity of 1 by inhibiting lactate transporters, resulting in blockage of the glycolytic process and impairment of mitochondrial potential. Additionally, the investigated Pt(IV) complexes selectively induce cell death in cancer cells, and the Pt(IV) complexes containing DCF ligands induce hallmarks of immunogenic cell death in cancer cells.
650    _2
$a platina $7 D010984
650    _2
$a diklofenak $x farmakologie $7 D004008
650    _2
$a ligandy $7 D008024
650    _2
$a organoplatinové sloučeniny $x farmakologie $7 D009944
650    _2
$a antiflogistika nesteroidní $x farmakologie $7 D000894
650    12
$a protinádorové látky $7 D000970
650    12
$a prekurzory léčiv $7 D011355
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a nádory $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a McGhie, Brondwyn S $u School of Science, Western Sydney University, Penrith South DC 1797, New South Wales, Australia
700    1_
$a Markova, Lenka $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, CZ-61200 Brno, Czech Republic $1 https://orcid.org/0000000316406163
700    1_
$a Novakova, Olga $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, CZ-61200 Brno, Czech Republic
700    1_
$a Kasparkova, Jana $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, CZ-61200 Brno, Czech Republic $u Department of Biophysics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000252795381
700    1_
$a Aldrich-Wright, Janice R $u School of Science, Western Sydney University, Penrith South DC 1797, New South Wales, Australia $1 https://orcid.org/0000000269436908
700    1_
$a Brabec, Viktor $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, CZ-61200 Brno, Czech Republic $1 https://orcid.org/0000000282331393 $7 jo20010087133
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 66, č. 12 (2023), s. 7894-7908
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37285472 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132742 $b ABA008
999    __
$a ok $b bmc $g 1963429 $s 1197276
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 66 $c 12 $d 7894-7908 $e 20230607 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace